CD20+ B cell depletion alters T cell homing

Area of Science:

• Immunology
• Autoimmune Diseases
• Therapeutic Mechanisms

Background:

• Anti-CD20 monoclonal antibodies (mAbs) are effective for autoimmune disorders, but their precise mechanisms remain unclear.
• Understanding these mechanisms is crucial for optimizing therapeutic strategies in autoimmune diseases.

Purpose of the Study:

• To elucidate the mechanistic basis for the clinical efficacy of anti-CD20 mAbs.
• To investigate the effects of anti-CD20 mAb therapy in a nonhuman primate model of experimental autoimmune encephalomyelitis (EAE).

Main Methods:

• Utilized common marmosets with EAE as a model for autoimmune-mediated inflammatory disorders.
• Analyzed secondary lymphoid organs (SLOs) following B cell depletion with anti-CD20 mAbs.
• Compared effects with mAbs targeting BLyS or APRIL.

Main Results:

• Anti-CD20 mAb treatment reduced immunostimulatory molecules (MHC class II, CD40, CD83, CD80/CD86) in SLOs.
• Antigen-presenting cells (APCs) from treated monkeys showed reduced responsiveness.
• B cell-depleted areas were repopulated by T cells expressing CD127 (IL-7R) and CCR7, unlike in BLyS/APRIL treated groups.

Conclusions:

• Anti-CD20 mAb therapy reduces the immunostimulatory environment in SLOs.
• Sustained CCR7 expression on T cells within SLOs may contribute to anti-CD20 mAb efficacy by limiting T cell circulation.